PDCD1 and cancer: Nevertheless, the revolutionary success of checkpoint inhibitors observed in the clinic to date across many cancer types may in part be due to revitalisation of ILC1s in addition to T cells, and highlights PD-1+ ILC1s as potential biomarkers in the future to stratify patient likelihood of response to immune checkpoint inhibitor treatment.